• Summer Internship Application

    Now accepting applications
    for the Summer Undergraduate Research Program

  • Tool to study RAS cancer mutations.

    Greehey CCRI Researchers co-author paper
    that looks at the reliability of a common research tool to study RAS cancer mutations.

  • Our little Heroes

    Translating Today's Discoveries
    in Childhood Cancer Research into Tomorrow's Treatments.

  • Using a Zebrafish model to fight cancer

    A $2 million CPRIT award will bring Siyuan Zheng, Ph.D.,
    to UT Health’s Greehey Children’s Cancer Research Institute.

  • Using a Zebrafish model to fight cancer

    Suprising finding using zebrafish model
    explains how recurring cancer may resist treatment.

  • Investigating the role of RNA binding  proteins and miRNAs in neurogenesis and brain tumor development

    The Penalva lab investigates the role of
    RNA binding proteins and miRNAs in neurogenesis and brain tumor development.

  • Pediatric Research Day Winner

    Greehey CCRI Student's present at Pediatric Research Day
    Mentored students from the Greehey CCRI and their research placed at the Pediatric Research Day Event

  • CPRIT Awards

    CPRIT awards $10.9 million to the Greehey institute for cancer research
    "focus on cancer in children and young adults, especially in our Hispanic population of South Texas"

Basic & Translational Science Award, RFA – Pilot Projects

The Greehey Children’s Cancer Research Institute, is soliciting proposals for pilot project awards. The primary goal of this program is to support early-stage collaborative basic and translational studies that will lead to increased interdisciplinary research likely to be incorporated into an NIH Program Project (PO1) focused on sarcomas in children, adolescents and young adults (AYA).

Why Support Research at Greehey Children's Cancer Research Institute

Researchers at Greehey Children’s Cancer Research Institute have developed more novel therapies in national trials than any other group in the US. Treatments developed by us are a standard of care in the U.S.A, Europe and Asia for high-risk solid tumors.


  • Seminar Series